Full Text View
Tabular View
No Study Results Posted
Related Studies
Effect of Aricept on Biomarkers (Acetylcholine, sAPP Alpha) In Cerebrospinal Fluid
This study has been completed.
Study NCT00987220   Information provided by Pfizer

First Received on September 28, 2009.   Last Updated on February 10, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Alzheimer's Disease
Dementia
Additional conditions recognized in this trial
Alzheimer Disease
More general conditions related to this trial
Brain Diseases
Central Nervous System Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Nervous System Diseases
Neurodegenerative Diseases
Tauopathies
Interventions listed in this trial
Placebo
donepezil (Aricept)
Additional drug interventions recognized in this trial
Acetylcholine
Donepezil
More general drug interventions related to this trial
Cardiovascular Agents
Central Nervous System Agents
Cholinergic Agents
Cholinergic Agonists
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Nootropic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Vasodilator Agents
Sponsors listed in this trial
Pfizer


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services